ArticleBMJ open2023

Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China.

Ziying Zhao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.